RRM2B
Ribonucleoside-diphosphate reductase subunit M2 B
Also known as: p53R2, RIR2B_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7LG56
- Gene
- RRM2B
- Ensembl
- ENSG00000048392
- Chromosome
- 8
- Canonical length
- 351 aa
- Protein class
- Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
This gene encodes the small subunit of a p53-inducible ribonucleotide reductase. This heterotetrameric enzyme catalyzes the conversion of ribonucleoside diphosphates to deoxyribonucleoside diphosphates. The product of this reaction is necessary for DNA synthesis. Mutations in this gene have been associated with autosomal recessive mitochondrial DNA depletion syndrome, autosomal dominant progressive external ophthalmoplegia-5, and mitochondrial neurogastrointestinal encephalopathy. Alternatively spliced transcript variants have been described.[provided by RefSeq, Feb 2010]
Canonical amino-acid sequenceUniProt
351 residues, UniProt reviewed canonical sequence.
>Q7LG56|RRM2B
1 MGDPERPEAA GLDQDERSSS DTNESEIKSN EEPLLRKSSR RFVIFPIQYP DIWKMYKQAQ
61 ASFWTAEEVD LSKDLPHWNK LKADEKYFIS HILAFFAASD GIVNENLVER FSQEVQVPEA
121 RCFYGFQILI ENVHSEMYSL LIDTYIRDPK KREFLFNAIE TMPYVKKKAD WALRWIADRK
181 STFGERVVAF AAVEGVFFSG SFAAIFWLKK RGLMPGLTFS NELISRDEGL HCDFACLMFQ
241 YLVNKPSEER VREIIVDAVK IEQEFLTEAL PVGLIGMNCI LMKQYIEFVA DRLLVELGFS
301 KVFQAENPFD FMENISLEGK TNFFEKRVSE YQRFAVMAET TDNVFTLDAD FLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RRM2B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 42 nTPM
Expression across tissuesHPA
Tissue
- parathyroid gland: 42 nTPM
- thyroid gland: 37 nTPM
- tongue: 33 nTPM
- skeletal muscle: 29 nTPM
- kidney: 23 nTPM
- choroid plexus: 23 nTPM
Single-cell type
- thymic myoid cells: 186 nCPM
- neutrophils: 142 nCPM
- fallopian tube ciliated cells: 92 nCPM
- respiratory ciliated cells: 82 nCPM
- endometrial ciliated cells: 69 nCPM
- neutrophil progenitors: 66 nCPM
Immune cell
- neutrophil: 23 nTPM
- basophil: 16 nTPM
- non-classical monocyte: 12 nTPM
- naive B-cell: 8.6 nTPM
- myeloid DC: 7.7 nTPM
- eosinophil: 7 nTPM
Brain region
- choroid plexus: 52 nTPM
- white matter: 31 nTPM
- spinal cord: 26 nTPM
- medulla oblongata: 26 nTPM
- hypothalamus: 25 nTPM
- pons: 25 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about RRM2B.
Disease | AllUniProt
Conditions RRM2B is implicated in, by any mechanism.
- Mitochondrial DNA depletion syndrome 8A (MTDPS8A) MIM:612075
- Mitochondrial DNA depletion syndrome 8B (MTDPS8B) MIM:612075
- Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5 (PEOA5) MIM:613077
- Rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunction (RCDFRD) MIM:268315
Disease | GeneticClinVar
45 pathogenic / likely-pathogenic of 463 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Mitochondrial DNA depletion syndrome 8a
- RRM2B-related mitochondrial disease
- Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5
- Rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunction
- Mitochondrial disease
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.7
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.21
- DepMap mean gene effect
- 0
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 2'-deoxyribonucleotide biosynthetic process
- deoxyribonucleotide biosynthetic process
- DNA repair
- DNA synthesis involved in DNA repair
- kidney development
- mitochondrial DNA replication
- negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator
- positive regulation of G0 to G1 transition
- positive regulation of G2/M transition of mitotic cell cycle
- renal system process
- response to amine
- response to oxidative stress
- ribonucleoside diphosphate metabolic process
- deoxyribonucleoside triphosphate metabolic process
Molecular functions
- identical protein binding
- metal ion binding
- ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RRM2B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RRM2B as an antibody target. Whether an autoantibody or antibody against RRM2B could matter depends on whether native RRM2B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RRM2B is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label RRM2B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...